<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02561741</url>
  </required_header>
  <id_info>
    <org_study_id>COV15010370</org_study_id>
    <nct_id>NCT02561741</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic, Bioavailability, and Safety Study of COV155 Administered in Healthy Subjects Under Fed and Fasted Conditions</brief_title>
  <official_title>An Open-Label, Randomized, Single-Dose, Three-Period Crossover Study to Evaluate the Pharmacokinetics, Bioavailability, and Safety of 3 Tablets of COV155 Administered in Normal, Healthy Subjects Under Fed (High- and Low-Fat Meal) and Fasted Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single center, single dose, open-label, randomized, 3-period, 6-sequence, crossover study
      conducted in normal healthy subjects to evaluate the effect of a high- and low-fat meal on
      the pharmacokinetics (PK), bioavailability (BA), and safety of COV155.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>48 hours</time_frame>
    <description>To evaluate the effect of food on the pharmacokinetics and bioavailability of COV155 following administration of the formulation given as 3 tablets in healthy subjects under fasting and fed (high- and low-fat) conditions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>48 hours</time_frame>
    <description>To evaluate the effect of food on the pharmacokinetics and bioavailability of COV155 following administration of the formulation given as 3 tablets in healthy subjects under fasting and fed (high- and low-fat) conditions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to achieve the maximum observed plasma concentration (Tmax)</measure>
    <time_frame>48 hours</time_frame>
    <description>To evaluate the effect of food on the pharmacokinetics and bioavailability of COV155 following administration of the formulation given as 3 tablets in healthy subjects under fasting and fed (high- and low-fat) conditions</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>COV155</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COV155</intervention_name>
    <description>COV155 tablets</description>
    <arm_group_label>COV155</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and/or non-pregnant, non-lactating or postmenopausal females, between 18 and 55
             years of age with a body mass index ≥ 19 and ≤ 30 kg/m2.

          2. All subjects biologically capable of having children must agree and commit to the use
             acceptable method(s) of birth control.

        Exclusion Criteria:

          1. ECG abnormalities or lab values greater than 2 times the upper limit of normal.

          2. Positive test results for human immunodeficiency virus (HIV), hepatitis B (HBsAg), or
             hepatitis C (IgG).

          3. Positive urine test results for drugs of abuse or history of drug/alcohol abuse.

          4. Use of marijuana, illicit drugs or nicotine-containing products.

          5. Donated or had significant loss of whole blood.

          6. Taken any prescription or nonprescription drugs, vitamins, minerals, or dietary/herbal
             supplements.

          7. History of abdominal and/or pelvic surgery, cholecystectomy, gastric bypass or gastric
             band surgery, or cardiothoracic surgery.

          8. History of anxiety, tension, agitation, psychiatric disorders, psychosis, or
             depression requiring hospitalization, psychotherapy, and/or medication.

          9. History of acute or chronic gastrointestinal disease or any condition that may
             interfere with the absorption, distribution, metabolism or excretion of the study
             treatment.

         10. History of seizures or diagnosis of epilepsy or other seizure disorder.

         11. History or laboratory evidence of bleeding or clotting disorder or condition.

         12. History or laboratory evidence of malignancy, stroke, diabetes, cardiac, renal, liver,
             and chronic pulmonary disease.

         13. Have or have a history of hay fever or seasonal allergies requiring over-the-counter
             or prescription medications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2015</study_first_submitted>
  <study_first_submitted_qc>September 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2015</study_first_posted>
  <last_update_submitted>October 18, 2016</last_update_submitted>
  <last_update_submitted_qc>October 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

